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Abstract
Aim To evaluate the relationship between macular
pigment optical density (MPOD) and glare disability in
open-angle glaucoma.
Methods A cross-sectional analysis of baseline data (88
subjects; median age, 67 (range 36–84) years) collected
during the Macular Pigment and Glaucoma Trial (ISRCTN
registry number: 56985060). MPOD at 0.25°, 0.5° and
1° of retinal eccentricity was measured using customised
heterochromatic flicker photometry. Mesopic contrast
sensitivity with glare (mCSg), photostress recovery time
(PRT) and self-reported glare symptoms were evaluated.
Fourier-domain optical coherence tomography was used
to analyse ganglion cell complex (GCC) and identify
foveal involvement.
Results Low spatial frequency (f) mCSg was
significantly correlated with MPOD at 0.25° (three cycles
per degree (cpd): r=0.25, p=0.04) and 0.5° (three cpd:
r=0.23, p=0.04) of retinal eccentricity. Those with foveal
GCC loss exhibited lower MPOD, had worse low spatial
fmCSg (1.5 cpd and 3 cpd, p=0.02 each) and prolonged
PRT (p=0.02) in comparison with those without foveal
involvement. The depth of central 10° field loss was
related to MPOD at all eccentricities (p<0.01 for all).
Those who reported glare symptoms had a significantly
lower MPOD at all retinal eccentricities (0.25° and 1°:
p=0.05 each; 0.5°: p=0.04), including those with foveal
involvement (0.25°: p=0.05; 0.5°: p<0.01; 1°: p=0.01).
Conclusions Macular pigment level may be an
important consideration among those experiencing
disability glare in glaucoma, including those with foveal
involvement.

Introduction

To cite: Siah WF, O’Brien C,
Loughman JJ. Br J Ophthalmol
Published Online First: [please
include Day Month Year].
doi:10.1136/
bjophthalmol-2017-310215

Disability glare impairs vision when light scatters
within the eye and casts a veiling luminance on
the retina. This causes a loss of image contrast and
decreases the visibility of objects near the source of
glare.1 Individuals with glaucoma commonly suffer
from disability glare, and this has been shown to be
present even in those with mild visual loss.2 3 The
aetiology of glare disability in glaucoma is poorly
understood and, currently, little can be offered to
the patient to alleviate this debilitating problem.
Recent evidence pertaining to the involvement of
the macula in glaucoma,4 however, has provided a
rationale for the exploration of macular pigment
(MP) in relation to functional (including glare
related) visual loss associated with glaucoma.
MP is composed of the hydroxycarotenoids lutein,
zeaxanthin and meso-zeaxanthin and is found to be

highly concentrated at the central macula.5 Apart
from its antioxidant properties and role as a filter
for short wavelength blue light, it is also believed
to play a beneficial role in visual performance.6–13 It
has been shown that healthy individuals with higher
macular pigment optical density (MPOD) experience less disability glare and demonstrate better
photostress recovery times (PRT).7 8 10 Furthermore, oral dietary MP supplementation has been
shown to increase MPOD and thereby improve
glare disability and PRT in healthy individuals.9 12
Similar to glaucoma, individuals with age-related
macular degeneration (AMD) commonly suffer
from disability glare even in the presence of early
disease.14 Dietary MP supplementation has also
been shown to increase MPOD and thereby elicit
an improvement in visual function including visual
acuity (VA), contrast sensitivity (CS) and subjective
glare recovery in AMD subjects.13
It has recently been demonstrated that MPOD is
lower in glaucomatous eyes relative to age-matched
normal eyes.15 16 Additionally, MPOD appears
to be lowest among those glaucoma subjects with
more severe structural damage and, in particular,
in the presence of retinal ganglion cell complex loss
involving the foveal region.17 Based on the evidence
that lower MPOD may be associated with disability
glare, this study was designed to evaluate whether
MP may relate to functional performance in the
glaucomatous eye.

Methods
Subjects

This paper analyses the baseline glaucoma-related functional data that were collected from the
Macular Pigment and Glaucoma Trial (ISRCTN
registry number: 56985060). Information on this
placebo-controlled, double-masked randomised
trial is available online at http://www.
isrctn.
com.
A total of 88 subjects with a diagnosis of openangle glaucoma were recruited. Written informed
consent was obtained from all subjects, and the
study adhered to the tenets of the Declaration of
Helsinki.
All subjects with a diagnosis of open-angle glaucoma displayed glaucomatous optic disc cupping
with compatible visual field (VF) loss and an open
anterior chamber angle on gonioscopy. Four different
types of open-angle glaucoma were considered for
this trial: (1) primary open-angle glaucoma, where
there is no associated ocular or systemic disease,
(2) normal-tension glaucoma, where intraocular
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pressure is within the normal range, (3) pseudoexfoliative glaucoma, which is characterised by fibrillar protein deposition in
the ocular anterior segment and (4) pigmentary glaucoma, which
is characterised by excessive pigment deposition in the ocular
anterior chamber angle.
The inclusion criteria were age >18 years, ETDRS LogMAR
VA of 0.30 or better and subject ability to adhere to the trial
protocol. Exclusion criteria comprised of any ocular disease such
as AMD or moderate-to-significant cataract (Lens Opacity Classification System III (LOCS III) grades C3-5, P3-5, NC3-5 or
NO3-5), previous ocular surgery other than cataract extraction
or glaucoma drainage procedure, presence of a blue-filter intraocular lens, underlying diagnosis of diabetes mellitus, consumption of an oral dietary MP supplement in the past 6 months
and the use of a miotic agent. The LOCS III18 grades cataracts
by type (cortical: C1-5 and posterior subcapsular: P1-5) and
nuclear appearance (nuclear colour: NC1-6 and nuclear opalescence: NO1-6). We used the LOCS III standards were used to
categorise eyes according to lens appearance as either ‘mild cataract’ (grades C1-2, P1-2, NC1-2 and/or NO1-2) or ‘no cataract’
(C0, P0, NC0 and/or NO0).
Details relating to age, gender, type of glaucoma, years diagnosed with glaucoma, history of smoking (current smoker,
ex-smoker and never smoked), body mass index (kg/m2) and lens
status (phakic vs pseudophakic) were recorded for each subject.
All subjects also underwent a comprehensive slit lamp biomicroscopy examination. If both eyes met the inclusion criteria,
the study eye was determined by random assignment using the
software programme Research Randomizer (V.4.0).19

Massachusetts, USA), which has been used in other MP
studies.17 25 This semiquantitative food frequency questionnaire
was used to quantify the dietary intake of lutein and zeaxanthin
among glaucoma subjects in order to control for any disparity in
MPOD between subgroups that may be caused by their respective diet.

CS with glare

The Optec 6500 device (Stereo Optical, Chicago, Illinois, USA)
was used to objectively measure mesopic (3.0 cd/m²) CS under
glare conditions (mesopic contrast sensitivity with glare (mCSg))
in all subjects. All testing was carried out on natural size pupils
under a constant ambient light. The Optec 6500 is based on
the Functional Acuity Contrast Test, which consists of a series
of sine-wave grating charts and is designed to test sensitivity
across five spatial frequencies (f) (1.5, 3, 6, 12 and 18 cycles per
degree (cpd)) and nine levels of contrast in 0.15 log CS decrements. The in-built glare source consists of 12 white LEDs that
are arranged circumferentially to the grating charts. The glare
source was preset to provide a medium intensity luminance of
42 lux.11 26 With distance glasses, if necessary, each subject was
required to identify the orientation of the grating (right, up or
left) without guessing, starting from the lowest spatial f and the
highest contrast. The last correct response for each spatial f was
plotted on a CS curve. When the subject was not able to see
the highest contrast setting at any spatial f, the result was documented as half the lowest CS value for that spatial f.

Photostress recovery

Measurement of the MP spatial profile

Heterochromatic flicker photometry (HFP) is a psychophysical technique for measuring MPOD that has been validated
against the absorption spectrum of in vitro preparations of
liposome-bound MP20 and shown to produce good test–retest
reliability when compared with other methods of measuring
MPOD.21 The HFP procedure is also minimally invasive, and
pupil dilatation is not necessary. Furthermore, it has been shown
that variation in pupil size has no effect on the final measurement and that the presence of cataract does not significantly
affect the measurement.22 23 A customised HFP (cHFP) approach
whereby the flicker frequency was optimised to take account
of individual differences in vision as influenced by age, ocular
disease or other factors was employed to optimise the task and
thereby minimise the likely variance between readings.24 MPOD
was measured at 0.25°, 0.5° and 1° under conditions of dimmed
light with a Macular Densitometer (Macular Metrics, Rehoboth, Massachusetts, USA) using the cHFP approach. Measurements taken at 7° of eccentricity were used as a reference point
where MPOD was assumed to be nil. Subjects were instructed
to view a stimulus consisting of a square wave alternating blue
(460 nm) and green (550 nm) flickering LED light source and
were required to ascertain the point at which the flicker stopped
or was minimally detectable (isoluminance match). For each test
point, five readings were obtained to produce a mean MPOD at
each eccentricity. Measurements were considered unreliable and
excluded from data analysis if there was a large variance between
measures (SD >0.05) for each test point.

PRT was measured using the portable, handheld MDD-2
Macular Adaptometer (Health Research Sciences, Lighthouse
Point, Florida, USA) device, which has previously been used in
other studies.27 28 It consists of a xenon flash source capable of
producing a 200 μs duration flash that is subsequently filtered to
block infrared and ultraviolet light before reaching the viewing
eye. Each subject was instructed to hold the device up close to
the study eye and to look through the 12 mm diameter viewing
aperture, which contained an +8 dioptre-focusing lens. At the
viewing aperture, the xenon flash reaches a peak irradiance of
4.5 W/cm2, and the stimulus is of 0.41-radian angular subtense.
At the start of the test, it was ascertained that each subject was
able to recognise a LED display number. The test was abandoned
if it was not identifiable to the subject. Afterwards, a pushbutton was pressed to produce the xenon flash. The subject was
required to call out a new numerical stimulus (single digit) that
appeared simultaneous to the flash. This prompted the examiner
to press a button to end the test. The time taken for the subject
to correctly identify the stimulus was recorded as the PRT. If
the response was incorrect, the test was repeated approximately
20 min later. An upper PRT limit of 60 s was incorporated into
the device, which automatically resets for a new test thereafter.
In the event that the subject did not respond within 60 s, the test
was abandoned.

Glare symptoms

Dietary intake of lutein and zeaxanthin

All glaucoma subjects completed the Lutein Zeaxanthin Questionnaire (Carotenoid & Health Laboratory, Jean Mayer USDA
Human Nutrition Center on Aging, Tufts University, Medford,

In the evaluation of subjective glare symptoms, the subjects
were asked the following question: ‘Do you suffer from glare?’.
Examples of different scenarios (glare from a poorly shielded
street lamp in a dark street; glare from an oncoming car headlight while driving at night; and glare from low-lying sun in
the winter) were used to provide context and assist them in
answering this question better.
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VF assessment

The Swedish Interactive Threshold Algorithm Standard 24-2
and 10–2 programmes available in the Humphrey Visual Field
Analyser (HVFA II, Carl Zeiss Meditec, Jena, Germany) were
used to assess differential light sensitivity as a measure of global
glaucomatous VF loss and residual visual function in the central
retina (within 10° of fixation), respectively. Mean deviation
(MD) was used to define the severity of glaucoma (extent of
functional loss) and was included in data analysis. Unreliable VF
plots, as determined by a fixation loss of >33% and/or false positive/negative rates >20%, were excluded from analysis.
MP is most concentrated within the central 1° of the fovea.
Although the 24-2 test pattern is useful in providing a global
scale of glaucomatous VF loss, it uses a 6° x 6° grid, which
only has four points within the central 4.2° radius of fixation.
In contrast, the 10–2 test pattern uses a 1° x 1° grid, with the
central four points corresponding to within 1.4° of the foveal
centre. The finding of a glaucomatous depression involving any
of the central four points of the 10–2 pattern deviation plots was
recorded (foveal visual loss). For the study of MP and central
visual function, we will focus on the MD of the 10–2 test for the
purpose of statistical analysis.

Fourier-domain optical coherence tomography (FD-OCT)

The ganglion cell complex (GCC) protocol from the RTVue
FD-OCT system (software V.5.1; Optovue, Fremont, California,
USA) was used to categorise subjects’ glaucoma by foveal involvement. This method had been described in detail previously.17 In
the GCC significance map, GCC thickness is colour coded by the
significance of GCC thickness reduction (red, p<1%; yellow,
p<5%; green, p≥5%). It was classified as ‘fovea-not-involved’
(ie, no GCC loss encroaching the fovea) if the perimeter of the
fovea zone was green in colour, and as ‘fovea-involved’ (ie, GCC
loss encroaching the fovea) if the red scale encroached up to the
perimeter of the fovea zone. The GCC subgroups allowed us to
compare visual function by foveal involvement, which was previously shown to be associated with significantly lower MPOD.

Statistical analysis

The SPSS statistical software package (V.22.0; IBM, New York,
USA) was used for data analysis. All variables were tested for
normality using either Kolmogorov-Smirnov test (if n>50)
or Shapiro-Wilk test (if n≤50). All data are presented as
mean±SD for normally distributed data and as median (range)
for non-normal distributions. Parametric tests (Pearson correlation coefficient and independent t-test) or non-parametric tests
(Spearman Rho test and Mann-Whitney U-test) were carried out
where appropriate. As the presence of a cataract can influence
mCSg results, we controlled for this factor in our analysis. Linear
regression analysis was also performed; R2 value signifies the
percentage of variability in the dependent variable that can be
explained by the model with the independent variable (MPOD).
When comparing categoric data, a χ2 test was used. A 5% statistical significance level of was adopted throughout the analysis.

Results

Successful MPOD measurement was obtained for 69 subjects
(78.4%) at 0.25° retinal eccentricity, 81 subjects (92%) at 0.5°
eccentricity and 59 subjects (67%) at 1° of eccentricity. No
significant relationship was observed between MPOD and
potential confounders for any relationship that might exist
between MPOD, visual function and other demographic parameters, including gender, time diagnosed with glaucoma, type of
Siah WF, et al. Br J Ophthalmol 2017;0:1–7. doi:10.1136/bjophthalmol-2017-310215

Figure 1 Graph demonstrates lower MPOD levels in those with
symptoms of glare compared with those who were symptom free.
MPOD, macular pigment optical density.
glaucoma, body mass index, lens status (mild cataract: yes or
no) or smoking status (p>0.05), except for age, which demonstrated a statistically significant relationship with MPOD at 0.5°
of retinal eccentricity only (r=−0.23, p=0.04). Subsequent
analyses involving MPOD at 0.5° of retinal eccentricity were
corrected for age.

Glare and photostress recovery

With controlling for the presence of mild cataract, MPOD was
found to be statistically significantly correlated with mCSg for
low spatial fs only, at both 0.25° (3 cpd: r=0.25, p=0.04) and
0.5° (3 cpd: r=0.23, p=0.04) of retinal eccentricity. No significant correlation was found between MPOD at 1° and mCSg.
Linear regression analyses showed a low R2 value between
MPOD and mCSg for low spatial fs (range 3%–7%). MannWhitney U-test was performed to evaluate any possible effect of
cataract on glare, and no significant differences in mCSg were
found at any f between those with and those without mild cataract (p values range 0.75–1.0).
In response to the glare symptoms question, 61% (n=54)
of subjects stated that they suffer from glare symptoms, with
a median duration of 4.5 years (range 0.5–30). Those who
suffered from glare symptoms had a significantly lower MPOD
at all eccentricities relative to those without glare symptoms
(figure 1), but no difference in terms of age, gender, length of
glaucoma diagnosis, body mass index, lens status or dietary
intake of lutein and zeaxanthin (table 1).
Valid PRT data were available for 73 subjects with a median of
19 s (range 8–59). The remaining subjects were either unable to
see the display number in the Macular Adaptometer (n=4) or to
respond within the 60 s limit following the xenon flash (n=11).
There was no correlation between MPOD and PRT (p>0.05 for
all).

VF loss

HVF 24-2 MD was significantly correlated with MPOD (r=0.33,
p<0.01 at 0.25°; r=0.33, p<0.01 at 0.5°; r=0.31, p=0.02 at
1°). The median MD for HVF 10–2 was −7.85 dB with a range
of −0.28 to −30.9. Using the 10–2 pattern deviation plots, we
found 51.5% (n=45) of subjects without foveal visual loss in
contrast to 48.9% (n=43) with foveal visual loss. However,
3
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Table 1

Self-reported glare symptoms and their characteristics
No glare

Glare

p

 0.25°, mean±SD

0.27±0.15

0.20±0.13

0.05*

 0.5°, mean±SD

0.22±0.13

0.16±0.12

0.04*

 1°, median (range)

0.15 (0–0.28)

0.09 (0–0.25)

0.05†

Age, mean±SD

64.5±9.6

66±10.4

0.51*

 Male, n (%)

16 (47.1)

32 (59.3)

 Female, n (%)

18 (52.9)

22 (40.7)

0.28‡

Length of glaucoma diagnosis,
median (range) (year)

6 (0.5–15)

6.5 (0.5–32)

0.60†

Body mass index, median (range)
(kg/m2)

26.3 (18.7–39)

25.3 (18.5–42)

0.80†

 Phakic, n (%)

30 (40)

45 (60)

 Pseudophakic, n (%)

4 (30.8)

9 (69.2)

0.56‡

MPOD

Gender

Lens status

Dietary intake, median (range) (mg/dL)
 Lutein

0.85 (0–13.2)

0.7 (0–5.2)

0.52†

 Zeaxanthin

0.1 (0–1.1)

0.1 (0–1.2)

0.15†

HVF 10–2 MD, median (range) (dB)

−7.85 (−0.28 to −7.75 (−1.02 to
−24.12)
−30.94)

0.44†

*Mann-Whitney U-test.
†Independent t-test.
‡χ2 test.
HVF, Humphrey visual field; MD, mean deviation; MPOD, macular pigment optical
density; p, significance (two tailed).

none of the latter displayed the findings of depression of all four
central points on the 10–2 pattern deviation plots suggesting the
possibility of reliable subject fixation of the Macular Densitometer stimulus targets to within 1.4° of the foveal centre. MPOD
at all retinal eccentricities were positively and statistically significantly correlated to the total amount of central visual field loss
as measured using the HVF 10–2 MD (r=0.33, p<0.01 at 0.25°;
r=0.33, p<0.01 at 0.5°; r=0.32, p=0.01 at 1°) (figure 2).
Linear regression analyses between MPOD (0.25°, 0.5° and 1° of
retinal eccentricity, respectively) and HVF 10–2 MD showed a
R2 ranging from 10% to 12%.

GCC subgroups

No confounding differences were found between the GCC
subgroups for gender, body mass index, length of time diagnosed with glaucoma, dietary intake or smoking habits except
age (‘fovea-not-involved’ vs ‘fovea-involved’, 62.6±10.4 years
vs 67.9±9.0, p=0.02), which was accounted for in subsequent
analyses. A general linear analysis confirmed that age did not
have a significant effect on parameters such as low spatial f
mCSg, PRT, HVF 10–2 MD and self-reported glare symptoms
(p>0.05 for all).

Low spatial f mCSg was significantly worse in the ‘fovea-involved’ subgroup compared with those without foveal involvement (1.5 cpd: Z=−2.26, p=0.02; 3 cpd: Z=−2.36, p=0.02)
(table 2). Additionally, the ‘fovea-involved’ subgroup had a
prolonged PRT in comparison with the ‘fovea-not-involved’
subgroup (Z=−2.41, p=0.02). In the ‘fovea-involved’ subgroup,
low spatial f mCSg was positively and statistically significantly
correlated with MPOD at 0.25° (1.5 cpd: r=0.37, p=0.02; 3
cpd: r=0.43, p=0.01) and 0.5° (1.5 cpd: r=0.29, p=0.05; 3
cpd: r=0.41, p=0.01) of retinal eccentricity, while no significant correlation was observed at 1° and higher mCSg spatial
fs. Of those with significant correlations, R2 was found to be
between 8% and 20%. No significant correlation was observed
between MPOD and mCSg in the ‘fovea-not-involved’ subgroup
(p>0.05 for all). Furthermore, MPOD was significantly lower
at all retinal eccentricities in those with foveal involvement who
reported glare symptoms compared with those without glare
symptoms (0.25°: p=0.05, t=−1.99; 0.5°: p<0.01, t=−2.92;
1°: p=0.01, t=−2.63), while no significant difference was
observed in the ‘fovea-not-involved’ subgroup (p>0.05 for all).
No significant correlation was observed between MPOD and
PRT within either GCC subgroup (p>0.05). Residual visual
function, as determined by HVF 10–2 MD, was significantly
worse (Z=−4.42, p<0.001) in the ‘fovea-involved’ subgroup
(median, −12.17 dB (range −0.28 to −26.78)) in comparison
with the ‘fovea-not-involved’ subgroup (median, −4.42 (range
−1.02 to −20.62)).

Discussion

This study demonstrates for the first time that a relationship
exists between MPOD and disability glare in the glaucomatous
eye. Low MP levels appear to be associated with poorer mCSg
at low spatial f and with increased symptoms of disability glare.
More interestingly, it appears that this relationship between
MPOD, mCSg and glare symptoms in individuals with glaucoma
is mediated by foveal involvement.
Glare-affected visual performance under mesopic conditions linearly correlates with the optical density of MP among
glaucoma subjects, particularly at lower spatial f. Our finding
that higher MP is associated with improved glare-related visual
performance is consistent with other reports,7 9 10 although some
studies have failed to replicate such findings for mesopic CS.12 28
The inconsistency in the results among studies may be explained
by the variation in population demographics, disease status and
study methodology. Mesopic conditions were prioritised herein
due to previous observations that impaired dark adaptation and
disability glare can be found in glaucoma,2 29 30 coupled with
evidence that glare-affected CS in the home environment is
compromised due to poorer lighting.31 Although the study of
MP in the glaucomatous eye is novel, other studies of MP in
the non-glaucomatous eye have indicated that higher MPOD

Figure 2 Scatter plots (A– C) show the correlation between MPOD and HVF 10–2 MD. HVF, Humphrey visual field; MD, mean deviation; MPOD,
macular pigment optical density.
4
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Table 2

Comparison of visual function between GCC subgroups
Fovea-not-involved subgroup

Fovea-involved subgroup

p

mCSg, median (range) (cpd)
 1.5

13 (3.5–50)

 3

20 (5–114)

9 (3.5–36)
10 (5–40)

0.023
0.018

 6

6 (6–85)

6 (6–45)

0.212

 12

4 (4–15)

4 (4–8)

0.127

 18
PRT, median (range) (s)
HVF 10–2 MD, median (range) (dB)

2 (2–4)
15 (8–59)
−4.42 (−1.02 to −20.62)

   2
20 (9–58)
−12.17 (−0.28 to −26.78)

0.388
0.015
<0.001

cpd, cycles per degree; GCC, ganglion cell complex; HVF, Humphrey visual field; mCSg, mesopic contrast sensitivity under glare condition; MD, mean deviation; PRT,
photostress recovery time.

and oral dietary MP supplementation can be beneficial towards
improving CS including CS under the influence of glare.7–10 12
Depressed levels of CS in the glaucomatous eye can be
explained, in part, by the disturbance at the macula.32 Our
finding that mCSg at low spatial f significantly correlates with
MPOD only in the ‘fovea-involved’ subgroup is not surprising
as the fovea represents the most central anatomic location where
MP density is highest. GCC thickness is linearly correlated with
MPOD16 17; lower central MP in those with foveal-involved
glaucoma may, therefore, be accountable, at least in part, for
glare disability in these eyes. However, given the weak association between MPOD and mCSg at low spatial fs, there are other
factors, in particular, retinal changes (retinal ganglion cells and
photoreceptors) in the glaucomatous eye that require consideration. Studies have demonstrated an association between
decreased CS in the glaucomatous eye and retinal ganglion cell
dysfunction33 or death.34 In addition, MP is localised to the
photoreceptor and retinal ganglion cell layers.5 Therefore, the
loss of retinal ganglion cells33 34 and photoreceptors,35 as encountered in glaucoma, can contribute to lower MPOD. We would
like to highlight that the retinal factors affecting CS and storage
of MP cannot be excluded in our experiments. Our finding of
a relationship between MPOD and mCSg in the glaucomatous
eye is novel and interesting, and future studies are required to
interpret this further.
Those who reported the experience of symptomatic glare
exhibited lower MPOD levels. This provides additional evidence
that glare disability is potentially linked to residual MP levels
in glaucoma. Our overall findings suggest that lower levels of
MPOD in the glaucomatous eye might represent a contributory factor to the effects of reduced mCSg and symptomatic
glare disability. Furthermore, we observed that the relationships
between MPOD and both mCSg and glare symptoms respectively are isolated to those with foveal GCC loss. This suggests
that further emphasis should be given to GCC analysis in glaucoma as foveal involvement relates to lower MPOD and poorer
residual visual function. There is substantial evidence to support
the role of MP in improving visual performance in healthy
eyes6–12 and in those with AMD.13 Oral dietary MP supplementation can augment MPOD and thereby effect an improvement
in visual function such as disability glare, PRT and CS under
glare conditions.9 12 13 Further research is needed to investigate
the therapeutic potential of oral dietary MP supplementation
for improving glare disability especially in those with foveal-involved glaucoma.
There is strong evidence in the literature to suggest good
structure–function relationship between macular RGC thinning
and macular VF loss as measured by HVF 10–2.4 We included
HVF 10–2 as an ancillary test to capture macular function for

this purpose. Our finding that HVF 10–2 MD was significantly
worse in the foveal GCC loss subgroup in comparison with those
without foveal involvement reinforces previous findings where
MPOD positively correlated with GCC thickness and where those
with foveal involvement displayed worse MPOD.16 17 Although
this study does not define the relationship between field loss,
MPOD and glare-related visual performance, the correlation
between central visual field loss and MPOD represents a novel
finding in the field of glaucoma and worthy of further research.
The mechanisms underlying an abnormal PRT among individuals with glaucoma remains unclear. Our findings indicate that a
relationship between MPOD and photostress recovery is confined
to those with foveal-involved glaucoma, who demonstrated a
prolonged PRT. In a study comparing healthy controls and those
with diabetes mellitus (with and without diabetic retinopathy
subgroups), there was no difference in PRT between groups.28
However, the study did not include those with diabetic maculopathy. There are conflicting results in the literature surrounding
the relationship between MPOD and PRT. In a study of normal
healthy controls, Stringham et al7 and Hammond et al10 each
showed that MPOD correlated with photostress recovery in
normal healthy controls while Loughman et al11 reported otherwise. The variability of findings in the published literature may
be explained by the differences in ocular pathology that were
studied and the methods used to evaluate photostress recovery
and MPOD, respectively.
There are limitations to this study. The HFP task can be challenging for some individuals, and this may affect the acquisition
of MPOD measurements. We have applied stringent criteria and
excluded readings that had large variances between them. This
may have resulted in a high exclusion rate in the MPOD data
that were available for statistical analysis. In the future, the use
of fundus autofluorescence to measure MPOD will help eliminate this problem.23 Another concern regarding the use of HFP
in measuring MPOD in the glaucomatous eye is the ability of the
subject to fixate and report the absence of flicker in the stimulus targets. In this study, 48.9% of the subjects demonstrated
some element of foveal visual field loss. This was determined by
referring to the central four points (corresponding to 1.4° of the
foveal centre) of the 10–2 pattern deviation plots. As no subjects
had evidence of light sensitivity depression in all central points,
and as all subjects demonstrated acceptable fixation stability
throughout the test, inability to reliably maintain central fixation
of the stimulus targets was not likely to be an issue. Despite this,
we do acknowledge that we cannot exclude the possibility that
patients’ glaucomatous foveal scotoma may have impacted their
fixation capacity.
The lack of a healthy control group could be considered a
drawback in this study. However, our main aim was to investigate
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the relationship between MPOD and glaucoma-related functional parameters, in particular glare disability, rather than the
comparison of visual function between glaucoma and controls.
The latter has previously been widely studied in the literature,
and it is known that functional measures such as CS with and
without glare and PRT are affected in those with glaucoma, and
therefore was not the primary focus in this study. The cross-sectional nature of the study also limits the interpretation of the
relationships that have been shown to exist but does serve to
guide future research.
Those with ‘fovea-involved’ glaucoma were older in comparison with those without foveal involvement, although the age
difference was small and not clinically meaningful. Coexisting
ocular pathologies such as cataract and macular changes are
more common with increasing age and may affect visual functions such as mCSg and PRT, respectively. We meticulously
excluded individuals with moderate-to-significant cataract using
the LOCS III grading, and therefore the possibility of a cataract
as a confounding factor on mCSg was minimised. One possible
limitation in this study is the absence of specific grading of the
type and severity of mild cataract in this study. We showed,
however, that cataract (those without cataract vs those with
mild cataract) had no effect on mCSg in our study subjects.
Furthermore, subsequent correlation analyses between MPOD
and mCSg were also controlled for the presence of mild cataract, so this potential limitation is relatively minor. Any individuals with coexisting AMD were not recruited into this study.
We also excluded those with an underlying diagnosis of diabetes
mellitus as the finding of concurrent diabetic retinopathy has
been linked with reduced MPOD.25 Any possible residual age-related confounding effects were controlled for in our statistical
analysis, thereby negating the potential issue.
Another limitation of this study is the inability to disentangle the effects of disability and discomfort glare. Although
the Optec 6500 device provides a consistent glare environment
for our experiments, it is not discernible whether the measurements recorded are solely disability glare alone. Discomfort glare
may be a contributing factor to participant experience of glare.
Our finding that those with self-reported glare symptoms have
lower MPOD relative to those without symptoms is a potentially
important finding. Interpretation of this finding, however, needs
to be tempered in relation to the nature of the question posed
to participants. The question was qualitative in nature and not
associated with a Likert or other scale to categorise responses.
Furthermore, the response was not probed to elucidate additional detail as to the nature of the symptoms where present.
Despite this limitation, our findings appear robust and therefore
warrant consideration for future work.

disability glare but may be a contributing factor. The study of
MP in glaucoma is of importance as the therapeutic potential
to increase MPOD with an oral dietary MP supplement to
improve disability glare is likely to appeal to patients with glaucoma exhibiting such symptoms should it work. To explore this
concept further, the Macular Pigment and Glaucoma Trial has
been designed to evaluate the MPOD response to an oral dietary
MP supplement and any effects on glare in glaucoma.
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